Jim Ranger‐Moore

433 total citations
13 papers, 238 citations indexed

About

Jim Ranger‐Moore is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jim Ranger‐Moore has authored 13 papers receiving a total of 238 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jim Ranger‐Moore's work include HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Advanced Biosensing Techniques and Applications (3 papers). Jim Ranger‐Moore is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Advanced Biosensing Techniques and Applications (3 papers). Jim Ranger‐Moore collaborates with scholars based in United States, Japan and Germany. Jim Ranger‐Moore's co-authors include Hiroaki Nitta, Brian Kelly, Thomas M. Grogan, Mark H. Stoler, Ruediger Ridder, Thomas C. Wright, Hitoshi Tsuda, Mahboobeh Safaeian, Shalini Singh and Nikolaus Wick and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and International Journal of Cancer.

In The Last Decade

Jim Ranger‐Moore

12 papers receiving 233 citations

Peers

Countries citing papers authored by Jim Ranger‐Moore

Since Specialization

Citations

This map shows the geographic impact of Jim Ranger‐Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jim Ranger‐Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jim Ranger‐Moore more than expected).

Fields of papers citing papers by Jim Ranger‐Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jim Ranger‐Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jim Ranger‐Moore. The network helps show where Jim Ranger‐Moore may publish in the future.

Co-authorship network of co-authors of Jim Ranger‐Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Jim Ranger‐Moore. A scholar is included among the top collaborators of Jim Ranger‐Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jim Ranger‐Moore. Jim Ranger‐Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Roche Digital Pathology Dx whole slide imaging system is comparable to traditional microscopy for primary diagnosis in surgical pathology 2025 ·American Journal of Clinical Pathology ·Keith A. Wharton, Jim Ranger‐Moore, (unknown), Alexander D. Borowsky, Cynthia Behling, (unknown), (unknown), Richard M. Feddersen, (unknown), Drew Baldwin, Richard F. Louie, (unknown), (unknown), (unknown), (unknown), Shalini Singh, (unknown)	0
2	Computer-aided scoring of erb-b2 receptor tyrosine kinase 2 (HER2) gene amplification status in breast cancer 2022 ·Journal of Pathology Informatics ·Alyson Yoder, Landon J. Inge, (unknown), (unknown), (unknown), Karel J. Zuiderveld, Jim Martin, (unknown), Mohammad Saleh Miri, (unknown), Bryan Irvine Lopez, Jim Ranger‐Moore, Christoph Guetter	6
3	Clinical validation of p16/Ki‐67 dual‐stained cytology triage of HPV‐positive women: Results from the IMPACT trial 2021 ·International Journal of Cancer ·Thomas C. Wright, Mark H. Stoler, Jim Ranger‐Moore, (unknown), (unknown), Mahboobeh Safaeian, Ruediger Ridder	44
4	Whole tumor section quantitative image analysis maximizes between-pathologists' reproducibility for clinical immunohistochemistry-based biomarkers 2017 ·Laboratory Investigation ·Michael Barnes, (unknown), (unknown), (unknown), Wendy Liu, Anindya Sarkar, (unknown), Yao Nie, Bryce P. Portier, (unknown), Olcay Sertel, Elizabeth Little, Bikash Sabata, Jim Ranger‐Moore	17
5	HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients 2016 ·Breast Cancer Research and Treatment ·Sasagu Kurozumi, (unknown), Masafumi Kurosumi, Hiroshi Matsumoto, Kenichi Inoue, Jun Horiguchi, Izumi Takeyoshi, Tetsunari Oyama, Jim Ranger‐Moore, D. Craig Allred, Eslie Dennis, Hiroaki Nitta	32
6	Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests 2015 ·BMC Health Services Research ·Mogens Vyberg, Søren Nielsen, Rasmus Røge, (unknown), Jim Ranger‐Moore, Eric Walk, (unknown), Ulrich‐Peter Rohr, Volker Teichgräber	16
7	New Methods for ALK Status Diagnosis in Non–Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In Situ Hybridization Assay 2013 ·Journal of Thoracic Oncology ·Hiroaki Nitta, Koji Tsuta, Akihiko Yoshida, Steffan N. Ho, Brian Kelly, (unknown), (unknown), Katie White, (unknown), Penny Towne, (unknown), Abigail McElhinny, Jim Ranger‐Moore, (unknown), Shalini Singh, Hitoshi Tsuda, Thomas M. Grogan	24
8	A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections 2012 ·Diagnostic Pathology ·Hiroaki Nitta, Brian Kelly, (unknown), Nikolaus Wick, Patrick Brunhoeber, (unknown), Shalini Singh, Jim Ranger‐Moore, (unknown), Hitoshi Tsuda, Thomas M. Grogan	49
9	Development of the SP120 rabbit monoclonal antibody for determining hENT1 status and predicting response to gemcitabine in pancreatic ductal adenocarcinoma. 2012 ·Journal of Clinical Oncology ·Stefan Boeck, Mitch Raponi, William D. Richardson, Penny Towne, Jeffrey D. Isaacson, Jim Ranger‐Moore, (unknown), (unknown), (unknown), Abigail McElhinny, Steffen Ormanns, Thomas Kirchner, William F. Regine, Kathryn Winter, Daniel Ansari, Lindsey Rolfe, Andrew R. Allen, Roland Andersson, Volker Heinemann, Adam P. Dicker	2
10	EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA Technology 2011 ·Clinical Cancer Research ·Céline Mascaux, Murry W. Wynes, Yasufumi Kato, Cindy Tran, Bernadette Reyna Asuncion, Jason M. Zhao, Mark Gustavson, Jim Ranger‐Moore, Fabien Gaire, Jun Matsubayashi, Toshitaka Nagao, Koichi Yoshida, (unknown), Norihiko Ikeda, Fred R. Hirsch	29
11	EXCESSIVE TIME TO TREATMENT DELAY IN RURAL NATIVE AMERICANS PRESENTING WITH ACUTE MYOCARDIAL INFARCTION: TEMPORAL TRENDS 1999-2006. 2007 ·Journal of Investigative Medicine ·(unknown), (unknown), Justin L. Sewell, (unknown), Jim Ranger‐Moore, (unknown), (unknown), (unknown), James M. Galloway, (unknown)	1
12	Poison Control Center--based syndromic surveillance for foodborne illness. 2005 ·PubMed ·(unknown), Jude McNally, Jim Ranger‐Moore, (unknown), Rodrigo Villar, (unknown), (unknown), MD Lebowitz, (unknown)	13
13	Workplace Tobacco Policy: Progress on a Winding Road 2001 ·Journal of Community Health ·(unknown), Jim Ranger‐Moore, (unknown), Robert G. Hall, Jason Brown, Hye‐Ryeon Lee	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact